TY - JOUR T1 - Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 4631 LP - 4637 VL - 33 IS - 10 AU - MASAAKI KAWAHARA AU - SHINJI ATAGI AU - KIYOSHI KOMUTA AU - HIROSHIGE YOSHIOKA AU - MASAYUKI KAWASAKI AU - YUKA FUJITA AU - TOSHIRO YONEI AU - FUMITAKA OGUSHI AU - KAORU KUBOTA AU - NAOYUKI NOGAMI AU - MICHIKO TSUCHIYA AU - KAZUHIKO SHIBATA AU - YOSHIO TOMIZAWA AU - KOICHI MINATO AU - KAZUYA FUKUOKA AU - KAZUHIRO ASAMI AU - TAKEHARU YAMANAKA AU - THE JAPAN MULTINATIONAL TRIAL ORGANIZATION Y1 - 2013/10/01 UR - http://ar.iiarjournals.org/content/33/10/4631.abstract N2 - Aim: Assessment of the efficacy of docetaxel plus carboplatin vs. paclitaxel plus carboplatin in Japanese patients with advanced non-small cell lung cancer (NSCLC). Patients and Methods: Chemotherapy-naïve patients were randomly assigned at a ratio of 2 to 1 to receive six cycles of either docetaxel (60 mg/m2) plus carboplatin [area under the curve (AUC)=6 mg/ml min] or paclitaxel (200 mg/m2) plus carboplatin (same dose), on day 1 every 21 days. The primary end-point was progression-free survival (PFS). Results: A total of 90 patients were enrolled. Overall response rate, median PFS and median survival time in the docetaxel-plus-carboplatin group and the paclitaxel-plus-carboplatin group were 23% vs. 33%, 4.8 months vs. 5.1 months, and 17.6 months vs. 15.6 months, respectively. The docetaxel-plus-carboplatin group had a higher incidence of grade 3 or 4 neutropenia (88% vs. 60%). Conclusion: Both regimens were similarly effective in Japanese patients with advanced NSCLC. ER -